Covalon Wins Tender at Prestigious King Abdullah Medical City in Mecca, Saudi Arabia

MISSISSAUGA, Ontario--()--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV), an advanced medical technologies company, today announced that, through its exclusive distribution partner, Covalon has been awarded a tender for both IV Clear and SurgiClear products at the prestigious King Abdullah Medical City in Mecca, Saudi Arabia. With over 1,500 beds, King Abdullah Medical City is one of the most influential hospitals in the Middle East, given its location in Mecca where over 14 million people will visit over the next 15 weeks.

King Abdullah Medical City is a very important showcase hospital for Covalon and demonstrates the momentum we have created on the ground in Saudi Arabia”, said Brian Pedlar, Covalon’s Chief Executive Officer. “We have a very strong team in Saudi Arabia that visits hospitals like King Abdullah Medical City every day, to introduce and support the sale of our products. We are looking forward to more successes in hospitals like King Abdullah Medical City throughout the Middle East.”

About Covalon
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

Contacts

Covalon Technologies Ltd.
Brian Pedlar, 905-568-8400 x 233
CEO
bpedlar@covalon.com
Toll free: 1-877-711.6055
Web site: www.covalon.com
Twitter: @covalon

Contacts

Covalon Technologies Ltd.
Brian Pedlar, 905-568-8400 x 233
CEO
bpedlar@covalon.com
Toll free: 1-877-711.6055
Web site: www.covalon.com
Twitter: @covalon